Understand the source comparison
Dihexa vs P21: Research Application Comparison
| Peptide | Primary Mechanism | Onset Timeline | Typical Dosing (Rodent) | Evidence Base Depth | Best Research Fit | Professional Assessment ||—|—|—|—|—|—|| Dihexa | c-Met receptor agonist (HGF mimetic) | 24-72 hours (acute synaptic effects) | 1-2 mg/kg SC/IP
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide | Primary Mechanism | Onset Timeline | Typical Dosing (Rodent) | Evidence Base Depth | Best Research Fit | Professional Assessment ||—|—|—|—|—|—|| Dihexa | c-Met receptor agonist (HGF mimetic) | 24-72 hours (acute synaptic effects) | 1-2 mg/kg SC/IP daily × 7 days | Limited (primarily one research group) | Short-term cognitive enhancement studies, acute synaptic signaling protocols | High theoretical potency but narrow replication data. Best for exploratory work where rapid effects are the primary endpoint || P21 (CNTF Fragment) | CNTF receptor complex activation → BDNF upregulation | 14-28 days (neurogenesis, structural plasticity) | 50-100 μg intranasal daily × 14-28 days | Extensive (multiple independent labs, two decades of data) | Long-term neuroplasticity studies, aging models, stroke/TBI recovery | Lower single-dose potency but reproducible across labs and models. The reliable choice for sustained cognitive or neuroprotective endpoints |